Maze Therapeutics, Inc. (MAZE)

Maze Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022
Period Ending	Aug 14, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Market Capitalization	592	-	-	-
Enterprise Value	357	-	-	-
Debt / Equity Ratio	0.10	0.14	4.94	0.32
Debt / EBITDA Ratio	-	0.40	-	-
Debt / FCF Ratio	-	0.36	-	-
Asset Turnover	0.01	1.07	-	-
Quick Ratio	13.29	9.52	1.79	4.81
Current Ratio	13.63	9.76	2.09	5.11
Return on Equity (ROE)	-62.95%	50.48%	-180.12%	-
Return on Assets (ROA)	-30.29%	23.07%	-55.63%	-
Return on Capital (ROIC)	-32.36%	25.42%	-63.77%	-
Return on Capital Employed (ROCE)	-	26.20%	-	-
Buyback Yield / Dilution	-727.28%	-19.33%	-13.82%	-

Updated Aug 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q